Richard Becker MD

PubMed

• Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.
  Wa Du, Madison Ringer, Darshini Desai, Golam Iftakhar Khandakar, Luis E Tron Esqueda
  Circulation. 2026-03-03
• 1 citations
  A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.
  Kalyani Ananthamohan, Tammy M Brady, Mohammed Arif, Stephen R Daniels, Bonita Falkner
  Journal of the American Heart Association. 2025-11-04
• 2 citations
  Sex as a biological variable: a contemporary perspective.
  Fatima Farrukh, Richard C Becker
  American Heart Journal. 2025-09-01

Journal Articles

• Translation and Clinical Development of Antithrombotic Aptamers  
  Nimjee SM, Povsic TJ, Sullenger BA, Becker RC, Nucleic Acid Ther, 1/16/2016
• Aspirin dosing in the primary and secondary prevention of cardiovascular events  
  Kim J, Becker RC, J Thomb Thrombolysis, 1/6/2016
• The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes  
  Becker RC, J Thomb Thrombolysis, 1/1/2016

Books/Book Chapters

• Consultative Hemostasis and Thrombosis 
  Chapter: Hemostatic Aspects of Cardiovascular Medicine. 
  Page 342 - 394Vemulapalli, S., Becker, R.C.Editors: Craig S. Kitchens, Craig M. Kessler and Barbara S. Konkle.Elsevier SaundersEdition 3rd,2013
• Advances in Cardiology. 
  Chapter: Protease-Activated Receptor-1 Inhibitors: A novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome. Antiplatelet Therapy in ACS and A-Fib. 
  Leonardi S, Tricoci P, Becker RCEditors: J.S. Borer.Karger2012
• Handbook of Experimental Pharmacology. 
  Chapter: Par-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombtosis. 
  Leonardi S, Becker RCSpringer-Verlag, Berlin, Heidelberg2012

Abstracts/Posters

• Factors Associated With Major Bleeding Events.
  Goodman SG, Wojdyla DM, Piccini JP, White, HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker, RC, Halperin JL, Hacke W, Singer DE, Ha..., JACC, 1/11/2014
• The Use Of Dual Antiplatlet Therapy And Patient Outcomes In Those Undergoing PCI In The Rocket AF Trial.
  Sherwood MW, Jones S, Cyr D, Becker R, Berkowitz S, Washam J, Breithardt G, Fox K, Halperin J, Hankey G, Singer D, Piccini J, Nessel C, Mahaffey K, Califf R, Hacke W, ..., JACC, 1/1/2014
• Use And Outcomes Of Antiarrhythmic Therapy In Patients With Atrial Fibrillation Receiving Oral Anticoagulation: Results From The Rocket AF Trial.
  Steinberg B, Hellkamp A, Lokhnygina Y, Halperin J, Breithardt G, Passman R, Hankey G, Patel M, Becker R, Singer D, Berkowitz S, Nessel C, Mahaffey K, Fox K, Califf R, ..., JACC, 1/1/2014

Lectures

• Current Management of Myocardial Infarction 
  1/1/1999

Other

• CD Rom Educational Service. 
  Becker RC, Up-To-Date
  1/1/2016
• On behalf of The Executive Steering Committee and the ROCKET AF Study Investigators Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF TRIAL. 
  Wong KSL, Hu DY, Oomman A, Tan R-S, Patel MR, Singer DE, Breithardt G, Mahaffey KW, Becker RC, Califf R, Fox KAA, Berkowitz SD, Hacke W, Hankey GJ, Stroke Online
  http://stroke.ahajournals.org/content/early/2014/04/23/STROKEAHA.113.002968
  1/1/2014
• Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease 
  Becker RC
  http://www.uptodate.com/contents/early-trials-of-platelet-glycoprotein-iib-iiia-receptor-inhibitors-
  UpToDate, Wolters Kluwer Health - 2012-07-02